The TGF-β signaling pathway has emerged as a master regulator of the immune contexture in the TME that orchestrates the interplay between tumor cells and CAFs, leading to changes in the ECM that excludes immune cells and possibly affecting immunotherapy responses. This evidence concerns the gene TGFB1 and neoplasm.